Skip to content

Comparison of reducing intraoperative blood loss using preoperative oral and intravenous tranexamic acid in bimaxillary surgery patients

Comparison of reducing intraoperative blood loss using preoperative oral and intravenous tranexamic acid in bimaxillary surgery patients

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20250702002
Enrollment
30
Registered
2025-07-02
Start date
2024-07-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intraoperative blood loss in patient undergoing bimaxillary orthognathic surgery Reducing intraoperative blood loss Tranexamic acid Orthognathic surgery Bimaxillary surgery

Interventions

Thirty minutes prior to surgery, patients in Group 1 received 2 grams of tranexamic acid in oral form, administered as 8 capsules of 250 mg each. After induction of general anesthesia, these patients
Experimental Drug,Active Comparator Drug
Oral tranexamic acid,IV tranexamic acid

Sponsors

Satha Lerwiwattaworn
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. American Society of Anesthesiologist (ASA): class I,II 2. Patients undergoing segmented and non-segmented Bimaxillary surgery without craniofacial syndromes such as cleft 3.Weight : 45-75 kg

Exclusion criteria

Exclusion criteria: 1. History of allergy to any medications relevant to the study, such as tranexamic acid, propofol, succinylcholine, or cisatracurium. 2. Presence of coagulation disorders (coagulopathy), either from medical history or abnormal laboratory findings such as platelet count, prothrombin time (PT), partial thromboplastin time (PTT), or bleeding time. 3. History of thromboembolic events, including deep vein thrombosis (DVT). 4. Uncontrolled hypertension. 5. Presence of cardiovascular diseases. 6. Uncontrolled diabetes mellitus. 7. Known liver or kidney dysfunction. 8. Current use of NSAIDs, antiplatelet agents, anticoagulants, or anticonvulsants. 9. Pregnant individuals or those experiencing abnormally heavy menstrual bleeding.

Design outcomes

Primary

MeasureTime frame
Total intraoperative blood loss end of surgery ml

Secondary

MeasureTime frame
Reduction in Hb concentration end of surgery g/dL,Calculated blood loss end of surgery ml,Operative time end of surgery hr,Blood transfusion discharged from hospital unit,ml,Adverse events discharged from hospital events

Countries

Thailand

Contacts

Public ContactSatha Lerwiwattaworn

Faculty of dentistry , Prince of Songkhla university

satang96@hotmail.com0813493353

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026